Table 4.
Best overall tumour responsea (RECIST v1.1) by presence of liver metastases at baseline.
| Response, n (%) | Without liver metastases (n = 23) | With liver metastases (n = 47) | All patients (N = 70) |
|---|---|---|---|
| Complete response | 0 | 0 | 0 |
| Partial response | 5 (22) | 0 | 5 (7) |
| Stable disease | 8 (35) | 14 (30) | 22 (31) |
| Progressive disease | 9 (39) | 27 (57) | 36 (51) |
| Not evaluable | 1 (4) | 6 (13) | 7 (10) |
| Objective response rate | 5 (22) | 0 | 5 (7) |
| Disease control rate ≥8 weeks | 13 (57) | 14 (30) | 27 (39) |
| Median duration of stable disease, weeks | 30 | 21 | 30 |
Duration of response results are not available for responders since only one patient had progression and the remaining four patients were still classified as responders at the time of analysis.
RECIST = Response Evaluation Criteria in Solid Tumors.
a
Only confirmed responses are shown: an additional two patients (with liver metastases) had an unconfirmed partial response and one patient with a partial response had a complete response that was confirmed after primary completion.